Elderly selection on geriatric index assessment

Por Tomasini, Pascale, Mascaux, Celine, Barlesi, Fabrice
Publicado no Ann Transl Med (2016)

Atezolizumab: feasible second-line therapy for patients with non-small cell lung cancer? A review of efficacy, safety and place in therapy

Por Jean, Fanny, Tomasini, Pascale, Barlesi, Fabrice
Publicado no Ther Adv Med Oncol (2017)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience

Por Greillier, Laurent, Tomasini, Pascale, Barlesi, Fabrice
Publicado no Ther Adv Respir Dis (2016)

The clinical utility of tumor mutational burden in non-small cell lung cancer

Por Greillier, Laurent, Tomasini, Pascale, Barlesi, Fabrice
Publicado no Transl Lung Cancer Res (2018)

Chemotherapy and immune checkpoint inhibitor combination, a new standard in squamous non-small cell lung cancer?

Por Travert, Camille, Tomasini, Pascale, Barlesi, Fabrice
Publicado no Transl Lung Cancer Res (2020)

Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC

Por Ciccolini, Joseph, Benzekry, Sébastien, Barlesi, Fabrice
Publicado no Br J Cancer (2020)

Ipilimumab: its potential in non-small cell lung cancer

Por Tomasini, Pascale, Khobta, Nataliya, Greillier, Laurent, Barlesi, Fabrice
Publicado em 2012

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes

Por Tomasini, Pascale, Barlesi, Fabrice, Mascaux, Celine, Greillier, Laurent
Publicado no Ther Adv Med Oncol (2016)

Immunologically effective dose: a practical model for immuno-radiotherapy

Por Serre, Raphaël, Barlesi, Fabrice, Muracciole, Xavier, Barbolosi, Dominique
Publicado no Oncotarget (2018)

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer?

Por Mogenet, Alice, Tomasini, Pascale, Greillier, Laurent, Barlesi, Fabrice
Publicado no Transl Lung Cancer Res (2019)

Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support

Por Ciccolini, Joseph, Benzekry, Sébastien, Lacarelle, Bruno, Barbolosi, Dominique, Barlési, Fabrice
Publicado no Proc Natl Acad Sci U S A (2015)

Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer

Por Tomasini, Pascale, Greillier, Laurent, Boyer, Arnaud, Jeanson, Arnaud, Barlesi, Fabrice
Publicado no J Thorac Dis (2018)

Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy

Por Sicard, Guillaume, Fina, Frédéric, Fanciullino, Raphaelle, Barlesi, Fabrice, Ciccolini, Joseph
Publicado no Pharmaceutics (2020)

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases

Por Tomasini, Pascale, Egea, Julie, Souquet-Bressand, Maxime, Greillier, Laurent, Barlesi, Fabrice
Publicado no Ther Adv Respir Dis (2019)

A patient reported outcome platform, a useful tool to improve monitoring and effective management of Covid-19–positive patients with cancer

Por Scotté, Florian, Minvielle, Etienne, Mir, Olivier, André, Fabrice, Barlesi, Fabrice, Soria, Jean-Charles
Publicado no Eur J Cancer (2020)

Domains of quality of life freely expressed by cancer patients and their caregivers: contribution of the SEIQoL

Por Hamidou, Zeinab, Baumstarck, Karine, Chinot, Olivier, Barlesi, Fabrice, Salas, Sébastien, Leroy, Tanguy, Auquier, Pascal
Publicado no Health Qual Life Outcomes (2017)

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesotheliom...

Por Elharrar, Xavier, Barbolosi, Dominique, Ciccolini, Joseph, Meille, Christophe, Faivre, Christian, Lacarelle, Bruno, André, Nicolas, Barlesi, Fabrice
Publicado no BMC Cancer (2016)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer

Por Schneider, Benjamin K., Boyer, Arnaud, Ciccolini, Joseph, Barlesi, Fabrice, Wang, Kenneth, Benzekry, Sebastien, Mochel, Jonathan P.
Publicado no CPT Pharmacometrics Syst Pharmacol (2019)

Neurocognitive function impairment after whole brain radiotherapy for brain metastases: actual assessment

Por Tallet, Agnes V, Azria, David, Barlesi, Fabrice, Spano, Jean-Philippe, Carpentier, Antoine F, Gonçalves, Antony, Metellus, Philippe
Publicado em 2012

Two Panels of Plasma MicroRNAs as Non-Invasive Biomarkers for Prediction of Recurrence in Resectable NSCLC

Por Sanfiorenzo, Céline, Ilie, Marius I., Belaid, Amine, Barlési, Fabrice, Mouroux, Jérôme, Marquette, Charles-Hugo, Brest, Patrick, Hofman, Paul
Publicado em 2013